Heart failure & cardiomyopathiesSecondary analysis
Effect of Finerenone on the Kansas City Cardiomyopathy Questionnaire (KCCQ) in Patients With HFmrEF/HFpEF
- Secondary analysis of the FINEARTS-HF randomised trial
- prespecified analysis
Authors' conclusion
Finerenone significantly reduced HF events and improved health status in patients with HF and mildly reduced ejection fraction/preserved ejection fraction across the spectrum of KCCQ-TSS at baseline.
Study context
- Population
- Patients with heart failure (HF) with mildly reduced EF/preserved EF5,986 (99.8%) with baseline KCCQ-TSS
- Participants
- 6,001 patients
- Comparison
- Finerenone vs placebo by baseline KCCQ-TSS
- Primary endpoint
- Composite of:
- CV death and total worsening HF events
- By baseline KCCQ-TSS tertile
Primary result
As reported in the abstract
Primary endpoint by baseline KCCQ-TSS tertile
Finerenone vs PlaceboRelative risk (95% CI)
tertile 1 (score 0-<57)
0.82(0.68–1.00)
tertile 2 (57-<81)
0.88(0.70–1.11)
tertile 3 (81-100)
0.88(0.69–1.14)
Secondary outcomes
| Outcome | mean difference (points) (95% CI) | P value | |
|---|---|---|---|
| Change in KCCQ-TSS from baseline (key secondary endpoint) · 12 months | 1.62 (0.69–2.56) | P < 0.001 | |
| −2024Difference, points (linear scale) |
Change in KCCQ-TSS from baseline (key secondary endpoint) · 12 months
- Numerically fewer finerenone-treated patients had clinically meaningful deterioration, and more had improvements in KCCQ-TSS
Original publication
Effect of Finerenone on the KCCQ in Patients With HFmrEF/HFpEF. J Am Coll Cardiol. Published 29 September 2024. doi:10.1016/j.jacc.2024.09.023
Summarised from the published abstract; every number is checked against it